We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

HUYA Bioscience International and Chipscreen Biosciences Initiate a Phase I Clinical Cancer Trial

News   May 24, 2007

 
HUYA Bioscience International and Chipscreen Biosciences Initiate a Phase I Clinical Cancer Trial
 
 
 

RELATED ARTICLES

Targeted Therapy Proves Effective Against Aggressive Blood Cancer in Clinical Trial

News

A multi-institutional clinical trial has given good results for a targeted therapy to treat a rare, aggressive blood cancer known as blastic plasmacytoid dendritic-cell neoplasm (BPDCN).

READ MORE

Kicking the Habit: Effectiveness of Different Forms of Nicotine Replacement Therapy

News

New evidence published in the Cochrane Library provides high quality evidence that people who use a combination of nicotine replacement therapies (a patch plus a short acting form, such as gum or lozenge) are more likely to successfully quit smoking than people who use a single form of the medicine.

READ MORE

New Version of CAR T-Cell Therapy Eliminates Severe Side Effects

News

An advance in the breakthrough cancer treatment known as CAR T-cell therapy appears to eliminate its severe side effects, making the treatment safer and potentially available in outpatient settings, a new USC study shows.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE